廣告
香港股市 將在 4 小時 11 分鐘 開市
  • 恒指

    16,742.95
    +239.85 (+1.45%)
     
  • 國指

    5,758.46
    +115.68 (+2.05%)
     
  • 上證綜指

    2,988.36
    +37.40 (+1.27%)
     
  • 道指

    39,069.11
    +456.87 (+1.18%)
     
  • 標普 500

    5,087.03
    +105.23 (+2.11%)
     
  • 納指

    16,041.62
    +460.72 (+2.96%)
     
  • Vix指數

    14.53
    -0.81 (-5.28%)
     
  • 富時100

    7,684.49
    +21.98 (+0.29%)
     
  • 紐約期油

    78.45
    +0.54 (+0.69%)
     
  • 金價

    2,034.30
    0.00 (0.00%)
     
  • 美元

    7.8221
    +0.0015 (+0.02%)
     
  • 人民幣

    0.9192
    +0.0005 (+0.05%)
     
  • 日圓

    0.0517
    -0.0001 (-0.12%)
     
  • 歐元

    8.4654
    +0.0049 (+0.06%)
     
  • Bitcoin

    51,656.58
    +601.61 (+1.18%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal

  • Ginkgo Bioworks Holdings Inc (NYSE: DNAagreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock transaction.

  • Zymergen stockholders will receive 0.9179 shares of Ginkgo's Class A common stock for each Zymergen share. The deal values Zymergen at approximately $300 million and would provide Zymergen shareholders about 5.25% pro forma ownership of Ginkgo.

  • Ginkgo plans to integrate Zymergen's core automation and software technologies for scaling strain engineering capacity into its foundry, including machine learning and data science tools for exploring genetic design space.

  • The agreement represents Ginkgo's largest acquisition to date and is expected to significantly enhance Ginkgo's platform by integrating robust automation and software capabilities.

  • Ginkgo customers will also benefit from expanding Ginkgo's library of biological assets ("Codebase") following the transaction.

  • The transaction is expected to be completed by the first quarter of 2023.

  • Price Action: DNA shares are down 4.62% at $2.79, and ZY stock is up 18.8% at $2.38 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.